Disclosed are 4-alkyl-spiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indol]-4-amine derivatives as represented by the general formula (I), wherein R1 and R2 independently of one another represent H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or the radicals R1 and R2 together form a morpholine or piperazine ring system; R3 represents alkyl which may be saturated or unsaturated, branched or unbranched, unsubstituted or substituted by one or more F, Cl, Br, I, CN, NH2, NO2, SH, cyclopentyl, cyclohexyl, CF3, OH, OCH3, OC2H5 or dimethylamino; X represents O, S, SO, SO2 or NR17; and wherein the remaining substituents are as defined herein. Further disclosed is a medicament which comprises at least one spirocyclic cyclohexane derivative as defined above and optionally comprising one or more suitable additives and/or auxiliary substances and/or additional active ingredients for the treatment of one or more of anxiety, stress, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive dysfunctions, learning and memory disorders, withdrawal symptoms, alcohol and/or drug and/or medicament abuse and/or dependency, sexual dysfunctions, cardiovascular diseases, hypotension, hypertension, tinnitus, pruritus, migraine, impaired hearing, deficient intestinal motility, impaired food intake, anorexia, obesity, locomotor disorders, diarrhoea, cachexia, urinary incontinence or as a muscle relaxant, anticonvulsive or anaesthetic or for co-administration in the case of treatment with an opioid analgesic or with an anaesthetic, for diuresis or antinatriuresis, anxiolysis, for modulation of motor activity, for modulation of neurotransmitter secretion and treatment of one or more neurodegenerative diseases associated therewith, for the treatment of withdrawal symptoms and/or for reducing the addictive potential of one or more opioids.
SPIROCYCLIC CYCLOHEXANE DERIVATIVES